C12N 2310/317
With an inverted bond
Official title: with an inverted bond, e.g. a cap structure
C12N2310/317 (With an inverted bond) appears on 386 US grants and 721 published applications in this corpus.
Search patents in C12N- Granted patents
- 386
- Published applications
- 721
- Assignees
- 179
- Inventors
- 746
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 9 | 0 |
| 1998 | 8 | 0 |
| 1999 | 2 | 0 |
| 2000 | 8 | 0 |
| 2001 | 8 | 3 |
| 2002 | 14 | 14 |
| 2003 | 9 | 42 |
| 2004 | 6 | 30 |
| 2005 | 3 | 75 |
| 2006 | 5 | 41 |
| 2007 | 2 | 23 |
| 2008 | 4 | 8 |
| 2009 | 10 | 43 |
| 2010 | 16 | 23 |
| 2011 | 25 | 15 |
| 2012 | 18 | 26 |
| 2013 | 14 | 14 |
| 2014 | 15 | 20 |
| 2015 | 13 | 28 |
| 2016 | 19 | 26 |
| 2017 | 23 | 34 |
| 2018 | 12 | 27 |
| 2019 | 22 | 28 |
| 2020 | 19 | 15 |
| 2021 | 16 | 19 |
| 2022 | 16 | 37 |
| 2023 | 15 | 45 |
| 2024 | 25 | 29 |
| 2025 | 8 | 28 |
| 2026 | 20 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- MRNA 5′-end cap analogs modified within phosphate residues, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide29 Sep 2026US 12,747,261 B2Explorna Therapeutics Sp. z o.o.
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- RNAi constructs for inhibiting ASGR1 expression and methods of use thereof1 Sep 2026US 12,723,248 B1Amgen Inc.
- Regulation of von Willebrand factor (VWF)18 Aug 2026US 12,709,754 B2Band Therapeutics, LLC
- Thrombus imaging aptamers and methods of using same4 Aug 2026US 12,697,401 B2Duke University
- RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use1 Oct 2026US 2026/0297591 A1Arrowhead Pharmaceuticals, Inc.
- Nucleic acid vaccine for activating nkg2c+ natural killer cells24 Sep 2026US 2026/0286356 A1Charite-Universitatsmedizin Berlin
- 5’-c alkyl substituted rna caps and methods of use17 Sep 2026US 2026/0272969 A1Nutcracker Therapeutics, Inc.
- Mapt sirna and uses thereof3 Sep 2026US 2026/0258408 A1Janssen Pharmaceutica NV
- Angiotensinogen-modulating compositions and methods of use thereof20 Aug 2026US 2026/0242783 A1ADARx Pharmaceuticals, Inc.
Most cited
By later US patents
- Oligonucleotides with inverted polarity531US 5,399,676 AGilead Sciences, Inc. · 1995
- Oligonucleotides with inverted polarity255US 5,527,899 AGilead Sciences, Inc. · 1996
- Three component chimeric antisense oligonucleotides254US 5,849,902 AOligos Etc. Inc. · 1998
- Conjugates and compositions for cellular delivery194US 7,491,805 B2Sirna Therapeutics, Inc. · 2009
- Inhibition of neovascularization using vegf-specific oligonucleotides135US 5,814,620 AChildren's Medical Center Corporation · 1998